Bolsa PT - Gráfico 3 Meses e Resumo de Sepracor Inc. [SEPR]

Sepracor Inc. - [Ticker: SEPR]
Última Trade		Range 52 Semanas	[0,000 - 0,000]
Hora da Última Trade	N/A - N/A	Price-Target 1 Ano	N/A
Variação	()	Capitalização Bolsista	3
Bid / Ask	N/A	EPS	0,00
Abertura		PER	12,69%
Máximo		Pagamento Dividendo	N/A
Mínimo		Data Ex-Dividendo	N/A
Fecho Anterior	0,000	Yield	N/A
Volume		Volume Médio (3m)	0
Nota: Os dados podem apresentar atraso de alguns minutos.

Ver cotações de outros activos

Intraday 5 dias 1 mes 3 meses 6 meses 1 ano 2 anos 5 anos 10 anos Use este gráfico no seu website!
Gráfico de Sepracor Inc. - [Ticker: SEPR]

Mudar para Gráfico de Análise Técnica Interactiva de Sepracor Inc.

Últimos 10 Tópicos no Fórum sobre Sepracor Inc.:

Não foram encontrados tópicos sobre Sepracor Inc. [SEPR], mas aconselha-se pesquisa no Fórum por tópicos relacionados com Sepracor Inc..

Notícias sobre Sepracor Inc. [SEPR]: (ordenadas por relevância)

First News Service

Asthma Medication Market 2017 ? Dulera, QVAR, Genentech Inc, Sepracor, Inc
First News Service
Worldwide Asthma Medication Market 2017 Analysis Report audits a Market Regions, Product Categories, with Sales, Business Revenue, Goods cost, Asthma Medication piece of the overall industry and Growth patterns, concentrating on driving Asthma ...

e mais »

Thinking About the Assessment of Risk: September 2017
Healio
Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly ...

New report shares details about the asthma medication market forecast to 2022
WhaTech
Dulera, QVAR, Glaxosmithkline plc, MAP Pharmaceuticals Inc, Merck & Co. Inc, AstraZeneca plc, Roche Holdings Ltd, Genentech Inc, Sepracor, Inc, Schering-Plough Corp, Sanofi-Aventis, Theravance Inc. The report also details the market positioning, ...

e mais »

Desloratadine Market Analysis, Recent Trends and Regional Growth Forecast by Types, Applications and Economic ...
satPRnews (press release)
Desloratadine Market Key Players Analysis: Pfizer, Teva, Wante Pharmaceutical?, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, Schering-Plough, Nanjing Hicin ...

e mais »

ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications
GlobeNewswire (press release)
Prior to HeartWare, Ms. Trevvett served in communications and investor relations roles at both Alkermes, Inc., a global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases, and Sepracor, ...

e mais »

Frequency Therapeutics Announces its Board of Directors and the Appointment of Marc A. Cohen as Chairman
Yahoo Finance
The Board Members include Tim Barberich, founder and former CEO and Chairman of Sepracor, Inc. (now known as Sunovion), Marc Kozin, Senior Advisor and former President of L.E.K. Consulting, Robert S. Langer, Sc.D., Frequency Co-founder and the ...

e mais »

Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development
Business Wire (press release)
?With their successful partnership from their time at Sepracor, Bill and our CMO, Dr. Tom Wessel, are a great team to rapidly advance our Phase 2 clinical trials in MS, ALS and Charcot-Marie-Tooth with FLX-787 which will be amongst the most advanced ...

e mais »

InvestorGuide

Cynapsus Therapeutics (CYNA) Stock Doubles on Sunovion Buyout
InvestorGuide
Shares of Cynapsus Therapeutics Inc. (CYNA) were trading up +21.44 or +116.78 percent to $39.80 per share in Thursday's premarket after news broke late yesterday that it would be acquired by Sunovion Pharmaceuticals Inc. Cynapsus Therapeutics stock ...
Sunovion Pharmaceuticals to Acquire Cynapsus TherapeuticsBusiness Wire (press release)

todos os 98 artigos de notícias »

PR Newswire (press release)

Genzyme Corporation Pays $5.885 Million To Resolve False Claims Act Allegations; Judgment Involving Cases ...
PR Newswire (press release)
Those defendants include Allergan, Inc., Amgen, Inc., Bradley Pharmaceuticals, Inc., Eisai, Inc., Mallincrodt, Inc., Novo Nordisk, Inc., Reliant Pharmaceuticals, Inc., Sepracor, Inc., and Upsher-Smith Laboratories, Inc. The settlement with Genzyme ...

e mais »

Rewire

Religious Imposition Proponents Find an Ally in the White House
Rewire
Stirrup worked as a senior legislative adviser at Venable LLP from 2003 to 2008. The firm's clients between those years included AstraZeneca Pharmaceuticals, Sepracor Inc, and the National Association of Spine Specialists. Another hire, Anna Pilato, is ...

Reuters

Dainippon to buy US drug firm Sepracor for $2.6 billion
Reuters
Sepracor, based in Marlborough, Massachusetts, had 2008 sales of $1.3 billion. Financial advisers to Dainippon Sumitomo were Nomura Securities and Thomas Weisel Partners LLC, while JP Morgan Securities Inc and Jeffries & Co advised Sepracor.
Drugmaker Sepracor Accepts $2.6B Buyout Offer from Japan's DainipponXconomy

todos os 485 artigos de notícias »

Sunovion Pharmaceuticals Inc. Announces Company Name Change
Business Wire (press release)
BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion), formerly Sepracor Inc. (Sepracor), announced today that it has formally changed its name. The change occurs on approximately the one year anniversary of the acquisition of Sepracor by ...

e mais »

TheChronicleHerald.ca (registration)

PEI's BioVectra buys former Sepracor plant in Windsor
TheChronicleHerald.ca (registration)
A Charlottetown drug manufacturer has acquired a mothballed Windsor pharmaceutical plant and plans to reopen the facility in early 2016. BioVectra Inc. purchased the former Sepracor Canada (Nova Scotia) Ltd. facility in May. The Sepracor operation ...
Charlottetown's BioVectra expanding, setting up in WindsorHants Journal

todos os 5 artigos de notícias »

CoLucid Pharmaceuticals Announces Election of Mark Corrigan, MD, to Board of Directors
GlobeNewswire (press release)
Dr. Corrigan was Executive Vice President, Research & Development of Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.) from April 2003 until December 2009. Prior to joining Sunovion Pharmaceuticals, he spent 10 years with Pharmacia & Upjohn, Inc.

e mais »

Flex Pharma Names William McVicar President and Chief Executive Officer
Business Wire (press release)
Prior to Inotek, he served as Vice President of Development Operations at Sepracor, where he oversaw the development, FDA review, and approval of multiple NDAs and SNDAs, including BROVANA®, XOPENEX MDI®, and XOPENEX's pediatric approval, which were ...

e mais »

Para mais notícias sobre Sepracor Inc. clique aqui:
Notícias de Sepracor Inc.